| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8679302 | Thrombosis Research | 2018 | 6 Pages |
Abstract
Consistent with the results from the EINSTEIN phase-III trials, findings of our routine practice study suggest that, in patients with unprovoked VTE, rivaroxaban has the potential to reduce both the risk of major bleeding and recurrent VTE compared to warfarin.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Craig I. Coleman, W. Frank Peacock, Thomas J. Bunz, Jan Beyer-Westendorf,